Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Celsion Corporation (CLSN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9000-0.0900 (-4.52%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.9900
Open2.0500
Bid1.9300 x 1100
Ask1.9200 x 1400
Day's Range1.9000 - 2.0807
52 Week Range1.8000 - 20.2500
Volume106,272
Avg. Volume328,640
Market Cap164.46M
Beta (5Y Monthly)2.10
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    Celsion's Formulated DNA Plasmid COVID-19 Vaccine Candidate Shows Activity Against Two Strains

    Celsion Corporation (NASDAQ: CLSN) has presented its PLACCINE platform technology at the World Vaccine Congress. "PLACCINE is demonstrating the potential to be a powerful platform that provides for rapid design capability for targeting two or more different variants of a single virus in one vaccine," said Dr. Khursheed Anwer, Chief Science Officer at Celsion. " Dr. Anwer continued, "In the murine model, our multivalent vaccine targeted against two different variants showed to be immunogenic as d

  • Benzinga

    3 Penny Stocks Insiders Are Buying

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. U.S. Energy The Trade: U

  • Zacks

    Celsion (CLSN) COVID Vaccine Effective in Pre-Clinical Studies

    Celsion (CLSN) announces data from pre-clinical studies for its investigational vaccine platform as a potential treatment for COVID-19.

Advertisement
Advertisement